(Q34375654)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

review article

1 reference

title

Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

Marilyn A Davies

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Douglas J Sheffler

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Bryan L Roth

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 January 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

CNS Neuroscience & Therapeutics

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

317-336

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

6 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00030.X

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00030.X

Biological perspectives. Aripiprazole: a third generation of antipsychotics begins?

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00030.X

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

21 January 2018

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

12 December 2020

In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol

1 reference

12 December 2020

Amisulpride: a review of its use in the management of schizophrenia.

1 reference

12 December 2020

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.

1 reference

12 December 2020

Partial dopamine agonists in the treatment of psychosis

1 reference

12 December 2020

Psychotropic drugs and the ECG: focus on the QTc interval

1 reference

12 December 2020

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

12 December 2020

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

12 December 2020

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride

1 reference

12 December 2020

Efficacy at G-protein-coupled receptors

1 reference

12 December 2020

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

1 reference

12 December 2020

Antipsychotics: impact on prolactin levels

1 reference

12 December 2020

Aripiprazole: profile on efficacy and safety

1 reference

12 December 2020

Aripiprazole: a review of its pharmacology and clinical use.

1 reference

12 December 2020

alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs

1 reference

12 December 2020

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

1 reference

12 December 2020

Aripiprazole: A New Atypical Antipsychotic Drug

1 reference

12 December 2020

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

12 December 2020

Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis

1 reference

12 December 2020

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

12 December 2020

New developments in the pharmacotherapy of schizophrenia

1 reference

12 December 2020

Treatment for mood and anxiety disorders: quetiapine and aripiprazole

1 reference

12 December 2020

Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein

1 reference

12 December 2020

Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone

1 reference

12 December 2020

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

1 reference

12 December 2020

Mechanism of new antipsychotic medications: occupancy is not just antagonism

1 reference

12 December 2020

Aripiprazole in an adult with Asperger disorder

1 reference

12 December 2020

Aripiprazole and extrapyramidal symptoms

1 reference

12 December 2020

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

12 December 2020

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

1 reference

12 December 2020

Serotonin receptors: their key role in drugs to treat schizophrenia

1 reference

12 December 2020

Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function

1 reference

12 December 2020

Aripiprazole-induced improvement in tardive dyskinesia

1 reference

12 December 2020

Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers

1 reference

12 December 2020

Aripiprazole and Parkinson's disease psychosis

1 reference

12 December 2020

Psychopharmacology: atypical antipsychotic dosing: the effect of co-medication with anticonvulsants.

1 reference

12 December 2020

Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?

1 reference

12 December 2020

Aripiprazole, a novel atypical antipsychotic drug

1 reference

12 December 2020

Focus on aripiprazole

1 reference

12 December 2020

Dopamine partial agonists: a new class of antipsychotic

1 reference

12 December 2020

The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release

1 reference

12 December 2020

Evidence-based pharmacotherapy of schizophrenia

1 reference

12 December 2020

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

1 reference

12 December 2020

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values

1 reference

12 December 2020

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

1 reference

12 December 2020

Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain

1 reference

12 December 2020

Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland

1 reference

12 December 2020

Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.

1 reference

12 December 2020

Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum

1 reference

12 December 2020

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

12 December 2020

Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.

1 reference

12 December 2020

10.1111/J.1527-3458.2004.TB00030.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15592581%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference